EDESA BIOTECH INC (EDSA:NASDAQ)
$6.27 0.33 (5.5556%)
Analysed EDESA BIOTECH INC (EDSA:NASDAQ) News Sources
Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit
31-03-2026
yahoo.com
Edesa Biotech (EDSA) Reaffirms 2026 Clinical Study Timeline for Vitiligo Treatment
20-04-2026
yahoo.com
Edesa Biotech Reaches US$68m Market Cap Benefiting Insider Stock Buying
23-04-2026
yahoo.com
Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results
14-05-2026
yahoo.com
Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference
19-05-2026
yahoo.com
EDSA: Preparing for Mid-2026 Start to Phase 2 Vitiligo Trial
22-05-2026
yahoo.com
Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury
05-06-2026
yahoo.com
Top Midday Stories: Lululemon Down After Fiscal Q1 Results; Amazon Engineers Criticize AI Spending; Hoffman to Exit Microsoft Board
05-06-2026
yahoo.com
Sector Update: Healthcare Stocks Gain Friday Afternoon
05-06-2026
yahoo.com
Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors
11-06-2026
yahoo.com
What is the current price of EDESA BIOTECH INC (EDSA:NASDAQ)?
The current price of EDESA BIOTECH INC (EDSA:NASDAQ) is $6.27.
EDESA BIOTECH INC (EDSA:NASDAQ) absolute price change since previous trading day?
The absolute price change of EDESA BIOTECH INC (EDSA:NASDAQ) since the previous trading day is $0.33.
EDESA BIOTECH INC (EDSA:NASDAQ) percentage price change since previous trading day?
The percentage price change of EDESA BIOTECH INC (EDSA:NASDAQ) since the previous trading day is 5.5556%.
What is the most recent average sentiment score for EDESA BIOTECH INC (EDSA:NASDAQ)?
The most recent average sentiment score for EDESA BIOTECH INC (EDSA:NASDAQ) is 73 out of 100.
What is the most recent average sentiment for EDESA BIOTECH INC (EDSA:NASDAQ)?
The most recent sentiment for EDESA BIOTECH INC (EDSA:NASDAQ) is .
SEC-8K** Filing Available For EDESA BIOTECH INC (EDSA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.